| Variable | N | Overall, N = 1,7021 | Treatment Groups | p-value2 | |
|---|---|---|---|---|---|
| Neoadjuvant Multiagent, N = 8341 | Neoadjuvant Multiagent Chemotherapy xrt, N = 8681 | ||||
| Age | 1,702 | 62.6193 (9.7819) | 62.7530 (9.9763) | 62.4908 (9.5954) | 0.40 |
| Sex | 1,702 | 0.35 | |||
| Female | 837 (49%) | 400 (48%) | 437 (50%) | ||
| Male | 865 (51%) | 434 (52%) | 431 (50%) | ||
| Race | 1,702 | 0.45 | |||
| Black | 120 (7.1%) | 65 (7.8%) | 55 (6.3%) | ||
| Other | 76 (4.5%) | 39 (4.7%) | 37 (4.3%) | ||
| White | 1,506 (88%) | 730 (88%) | 776 (89%) | ||
| Type of Insurance | 1,702 | 0.63 | |||
| Medicaid | 79 (4.6%) | 38 (4.6%) | 41 (4.7%) | ||
| Medicare | 697 (41%) | 352 (42%) | 345 (40%) | ||
| Not Insured | 17 (1.0%) | 6 (0.7%) | 11 (1.3%) | ||
| Private Insurance/Managed Care/Goverment | 885 (52%) | 428 (51%) | 457 (53%) | ||
| Unknown | 24 (1.4%) | 10 (1.2%) | 14 (1.6%) | ||
| Regions | 1,702 | <0.001 | |||
| Midwest | 456 (27%) | 208 (25%) | 248 (29%) | ||
| Northeast | 433 (25%) | 220 (26%) | 213 (25%) | ||
| South | 499 (29%) | 216 (26%) | 283 (33%) | ||
| Unknown | 24 (1.4%) | 14 (1.7%) | 10 (1.2%) | ||
| West | 290 (17%) | 176 (21%) | 114 (13%) | ||
| Income | 1,702 | 0.24 | |||
| < $38,000 | 196 (12%) | 96 (12%) | 100 (12%) | ||
| >=$63,000 | 662 (39%) | 321 (38%) | 341 (39%) | ||
| $38,000-$47,999 | 362 (21%) | 184 (22%) | 178 (21%) | ||
| $48,000-$62,999 | 474 (28%) | 226 (27%) | 248 (29%) | ||
| Unknown | 8 (0.5%) | 7 (0.8%) | 1 (0.1%) | ||
| No High School Degree | 1,702 | 0.33 | |||
| <7.0% | 541 (32%) | 269 (32%) | 272 (31%) | ||
| >=21.0% | 166 (9.8%) | 85 (10%) | 81 (9.3%) | ||
| 13.0-20.9% | 351 (21%) | 171 (21%) | 180 (21%) | ||
| 7.0-12.9% | 637 (37%) | 303 (36%) | 334 (38%) | ||
| Unknown | 7 (0.4%) | 6 (0.7%) | 1 (0.1%) | ||
| Population Density | 1,702 | 0.56 | |||
| Metro | 1,381 (81%) | 677 (81%) | 704 (81%) | ||
| Rural | 33 (1.9%) | 14 (1.7%) | 19 (2.2%) | ||
| Unknown | 43 (2.5%) | 25 (3.0%) | 18 (2.1%) | ||
| Urban | 245 (14%) | 118 (14%) | 127 (15%) | ||
| Charlson-Deyo Score | 1,702 | 0.085 | |||
| >=3 | 34 (2.0%) | 10 (1.2%) | 24 (2.8%) | ||
| 0 | 1,191 (70%) | 595 (71%) | 596 (69%) | ||
| 1 | 397 (23%) | 187 (22%) | 210 (24%) | ||
| 2 | 80 (4.7%) | 42 (5.0%) | 38 (4.4%) | ||
| TNM Clinical T | 1,702 | ||||
| c0 | 1 (<0.1%) | 1 (0.1%) | 0 (0%) | ||
| c1 | 9 (0.5%) | 6 (0.7%) | 3 (0.3%) | ||
| c2 | 86 (5.1%) | 57 (6.8%) | 29 (3.3%) | ||
| c3 | 1,000 (59%) | 509 (61%) | 491 (57%) | ||
| c4 | 564 (33%) | 234 (28%) | 330 (38%) | ||
| cX | 40 (2.4%) | 27 (3.2%) | 13 (1.5%) | ||
| Unknown | 2 (0.1%) | 0 (0%) | 2 (0.2%) | ||
| TNM Clinical N | 1,702 | 0.20 | |||
| c0 | 1,086 (64%) | 532 (64%) | 554 (64%) | ||
| c1 | 544 (32%) | 261 (31%) | 283 (33%) | ||
| cX | 70 (4.1%) | 41 (4.9%) | 29 (3.3%) | ||
| Unknown | 2 (0.1%) | 0 (0%) | 2 (0.2%) | ||
| Clinical Downstaging | 1,702 | <0.001 | |||
| No | 667 (39%) | 405 (49%) | 262 (30%) | ||
| Unknown | 356 (21%) | 144 (17%) | 212 (24%) | ||
| Yes | 679 (40%) | 285 (34%) | 394 (45%) | ||
| Surgery Type | 1,702 | 0.47 | |||
| Pancreatectomy, NOS | 16 (0.9%) | 9 (1.1%) | 7 (0.8%) | ||
| Partial pancreatectomy, distal | 219 (13%) | 97 (12%) | 122 (14%) | ||
| Total | 214 (13%) | 112 (13%) | 102 (12%) | ||
| Unknown | 82 (4.8%) | 38 (4.6%) | 44 (5.1%) | ||
| Whipple | 1,171 (69%) | 578 (69%) | 593 (68%) | ||
| Surgical Margins | 1,702 | <0.001 | |||
| R0 | 1,264 (74%) | 571 (68%) | 693 (80%) | ||
| R1 | 197 (12%) | 130 (16%) | 67 (7.7%) | ||
| R2 | 13 (0.8%) | 7 (0.8%) | 6 (0.7%) | ||
| Unknown | 228 (13%) | 126 (15%) | 102 (12%) | ||
| Tumor Grade | 1,702 | 0.043 | |||
| Moderately differentiated | 443 (26%) | 242 (29%) | 201 (23%) | ||
| Poorly differentiated | 304 (18%) | 147 (18%) | 157 (18%) | ||
| Unknown | 834 (49%) | 386 (46%) | 448 (52%) | ||
| Well differentiated, differentiated | 121 (7.1%) | 59 (7.1%) | 62 (7.1%) | ||
|
1
Statistics presented: Mean (SD); n (%)
2
Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence; Fisher's exact test
|
|||||